"Thymidine Phosphorylase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the transfer of 2-deoxy-D-ribose from THYMIDINE to orthophosphate, thereby liberating thymidine.
| Descriptor ID |
D013939
|
| MeSH Number(s) |
D08.811.913.400.725.850.500 D23.050.301.500.600.925 D23.050.705.552.600.850
|
| Concept/Terms |
Thymidine Phosphorylase- Thymidine Phosphorylase
- Platelet-Derived Endothelial Cell Growth Factor
- Platelet Derived Endothelial Cell Growth Factor
- PD-ECGF
- Gliostatin
|
Below are MeSH descriptors whose meaning is more general than "Thymidine Phosphorylase".
Below are MeSH descriptors whose meaning is more specific than "Thymidine Phosphorylase".
This graph shows the total number of publications written about "Thymidine Phosphorylase" by people in this website by year, and whether "Thymidine Phosphorylase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thymidine Phosphorylase" by people in Profiles.
-
Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity. Front Immunol. 2022; 13:988071.
-
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18.
-
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar; 96(3):810-7.
-
Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil). Cancer Chemother Pharmacol. 1981; 7(1):55-9.